nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Michael Thomas,1,2 David R Spigel,3 Robert M Jotte,4 Michael McCleod,5 Mark A Socinski,6 Ray D Page,7 Laurent Gressot,8 Jeanna Knoble,9 Oscar Juan,10 Daniel Morgensztern,11 Dolores Isla,12 Edward S Kim,13 Howard West,14 Amy Ko,15 Teng Jin Ong,15 Nataliya Trunova,15 Cesare Gridelli16 On beha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	nab-paclitaxel non-small cell lung cancer quality of life response squamous Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/e012459543d645ccac9379a0cc907457
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e012459543d645ccac9379a0cc907457
record_format	dspace
spelling	oai:doaj.org-article:e012459543d645ccac9379a0cc9074572021-12-02T00:22:18Znab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy1179-2728https://doaj.org/article/e012459543d645ccac9379a0cc9074572017-10-01T00:00:00Zhttps://www.dovepress.com/nab-paclitaxelcarboplatin-induction-in-squamous-nsclc-longitudinal-qua-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Michael Thomas,1,2 David R Spigel,3 Robert M Jotte,4 Michael McCleod,5 Mark A Socinski,6 Ray D Page,7 Laurent Gressot,8 Jeanna Knoble,9 Oscar Juan,10 Daniel Morgensztern,11 Dolores Isla,12 Edward S Kim,13 Howard West,14 Amy Ko,15 Teng Jin Ong,15 Nataliya Trunova,15 Cesare Gridelli16 On behalf of ABOUND.sqm investigators 1Department of Thoracic Oncology/Internal Medicine, Thoraxklinik im Universitätsklinikum Heidelberg, 2Translational Lung Research Center Heidelberg, Heidelberg, Germany; 3Sarah Cannon Research Institute, Nashville, TN, 4Department of Medical Oncology/Hematology, Rocky Mountain Cancer Centers, Denver, CO, 5Florida Cancer Specialists, Fort Myers, 6Florida Hospital Cancer Institute, Orlando, FL, 7The Center for Cancer and Blood Disorders, Fort Worth, 8North Cypress Cancer Center, Cypress, TX, 9The Mark H. Zangmeister Center, Columbus, OH, USA; 10Department of Medical Oncology, Hospital Universitari i Politécnic La Fe, Valencia, Spain; 11Department of Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA; 12Department of Medical Oncology, University Hospital Lozano Blesa, Zaragoza, Spain; 13Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, 14Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, 15Celgene Corporation, Summit, NJ, USA; 16Department of Oncology/Hematology, S.G. Moscati Hospital, Avellino, Italy Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy. Methods: Patients received nab-paclitaxel 100 mg/m2 days 1, 8, 15 + carboplatin area under the curve 6 mg•min/mL day 1 (q3w) for four cycles. QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and Euro-QoL-5 Dimensions-5 Levels (EQ-5D-5L) at baseline and each cycle (day 1). Results: Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1 postbaseline QoL assessment and were QoL evaluable. LCSS average total score and symptom burden index improved from baseline throughout four cycles. In the LCSS pulmonary symptoms score, 46% of patients reported clinically meaningful improvement (≥10 mm visual analog scale) from baseline. Individual EQ-5D-5L dimensions remained stable/improved in ≥83% of patients; ≈33% reported complete resolution of baseline problems at least once during four cycles. Generally, responders (unconfirmed complete/partial response) had higher scores vs nonresponders. Conclusion: In patients with squamous NSCLC, four cycles of nab-paclitaxel/carboplatin demonstrated clinically meaningful QoL improvements, with greater benefits in responders vs nonresponders. Keywords: nab-paclitaxel, non-small cell lung cancer, quality of life, response, squamousThomas MSpigel DRJotte RMMcCleod MSocinski MAPage RDGressot LKnoble JJuan OMorgensztern DIsla DKim ESWest HKo AOng TJTrunova NGridelli CDove Medical Pressarticlenab-paclitaxelnon-small cell lung cancerquality of liferesponsesquamousNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 207-216 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	nab-paclitaxel non-small cell lung cancer quality of life response squamous Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	nab-paclitaxel non-small cell lung cancer quality of life response squamous Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Thomas M Spigel DR Jotte RM McCleod M Socinski MA Page RD Gressot L Knoble J Juan O Morgensztern D Isla D Kim ES West H Ko A Ong TJ Trunova N Gridelli C nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
description	Michael Thomas,1,2 David R Spigel,3 Robert M Jotte,4 Michael McCleod,5 Mark A Socinski,6 Ray D Page,7 Laurent Gressot,8 Jeanna Knoble,9 Oscar Juan,10 Daniel Morgensztern,11 Dolores Isla,12 Edward S Kim,13 Howard West,14 Amy Ko,15 Teng Jin Ong,15 Nataliya Trunova,15 Cesare Gridelli16 On behalf of ABOUND.sqm investigators 1Department of Thoracic Oncology/Internal Medicine, Thoraxklinik im Universitätsklinikum Heidelberg, 2Translational Lung Research Center Heidelberg, Heidelberg, Germany; 3Sarah Cannon Research Institute, Nashville, TN, 4Department of Medical Oncology/Hematology, Rocky Mountain Cancer Centers, Denver, CO, 5Florida Cancer Specialists, Fort Myers, 6Florida Hospital Cancer Institute, Orlando, FL, 7The Center for Cancer and Blood Disorders, Fort Worth, 8North Cypress Cancer Center, Cypress, TX, 9The Mark H. Zangmeister Center, Columbus, OH, USA; 10Department of Medical Oncology, Hospital Universitari i Politécnic La Fe, Valencia, Spain; 11Department of Medical Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA; 12Department of Medical Oncology, University Hospital Lozano Blesa, Zaragoza, Spain; 13Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, 14Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, 15Celgene Corporation, Summit, NJ, USA; 16Department of Oncology/Hematology, S.G. Moscati Hospital, Avellino, Italy Background: Longitudinal data on the impact of treatment on quality of life (QoL) in advanced non-small cell lung cancer (NSCLC) are limited. In this palliative setting, treatment that does not deteriorate QoL is key. Here we report longitudinal QoL in patients with squamous NSCLC, receiving ≤4 cycles of nab-paclitaxel/carboplatin combination chemotherapy. Methods: Patients received nab-paclitaxel 100 mg/m2 days 1, 8, 15 + carboplatin area under the curve 6 mg•min/mL day 1 (q3w) for four cycles. QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and Euro-QoL-5 Dimensions-5 Levels (EQ-5D-5L) at baseline and each cycle (day 1). Results: Two-hundred and six lesion-response-evaluable patients completed baseline + ≥1 postbaseline QoL assessment and were QoL evaluable. LCSS average total score and symptom burden index improved from baseline throughout four cycles. In the LCSS pulmonary symptoms score, 46% of patients reported clinically meaningful improvement (≥10 mm visual analog scale) from baseline. Individual EQ-5D-5L dimensions remained stable/improved in ≥83% of patients; ≈33% reported complete resolution of baseline problems at least once during four cycles. Generally, responders (unconfirmed complete/partial response) had higher scores vs nonresponders. Conclusion: In patients with squamous NSCLC, four cycles of nab-paclitaxel/carboplatin demonstrated clinically meaningful QoL improvements, with greater benefits in responders vs nonresponders. Keywords: nab-paclitaxel, non-small cell lung cancer, quality of life, response, squamous
format	article
author	Thomas M Spigel DR Jotte RM McCleod M Socinski MA Page RD Gressot L Knoble J Juan O Morgensztern D Isla D Kim ES West H Ko A Ong TJ Trunova N Gridelli C
author_facet	Thomas M Spigel DR Jotte RM McCleod M Socinski MA Page RD Gressot L Knoble J Juan O Morgensztern D Isla D Kim ES West H Ko A Ong TJ Trunova N Gridelli C
author_sort	Thomas M
title	nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
title_short	nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
title_full	nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
title_fullStr	nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
title_full_unstemmed	nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
title_sort	nab-paclitaxel/carboplatin induction in squamous nsclc: longitudinal quality of life while on chemotherapy
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/e012459543d645ccac9379a0cc907457
work_keys_str_mv	AT thomasm nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT spigeldr nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT jotterm nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT mccleodm nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT socinskima nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT pagerd nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT gressotl nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT knoblej nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT juano nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT morgenszternd nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT islad nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT kimes nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT westh nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT koa nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT ongtj nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT trunovan nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy AT gridellic nabpaclitaxelcarboplatininductioninsquamousnsclclongitudinalqualityoflifewhileonchemotherapy
_version_	1718403836654125056

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

Ejemplares similares